

Information for Patient

ABECMA may cause side effects that are life-threatening and can lead to death.

Call your healthcare provider or get emergency help right away if you get any of the following:

- Difficulty breathing
- Fever (100.4°F/38°C or higher)
- Chills/shivering
- Confusion
- Dizziness or lightheadedness
- Shaking or twitching (tremor)
- Fast or irregular heartbeat
- Severe fatigue
- Severe nausea, vomiting, or diarrhea

ABECMA® is a trademark of Celgene Corporation, a Bristol-Myers Squibb Company.

© 2021 Celgene Corporation, a Bristol-Myers Squibb Company. All rights reserved.



Patient Wallet Card

Have this card with you at all times. Show it to any doctor who sees you and when you go to the hospital.

- Tell any healthcare provider who sees you that you are being treated with ABECMA®.
- For at least 4 weeks after receiving ABECMA, you should plan to stay within 2 hours of the location where you received treatment.
- Refrain from driving or operating heavy or potentially dangerous machines until at least 8 weeks after ABECMA administration.

Name of ABECMA Treating Oncologist

Office Phone Number

After-hours Phone Number

Hospital Name (for Management of ABECMA Side Effects)

Date of ABECMA Infusion

03/21 US-REMS-ABM190003

www.AbecmaREMS.com

Information for the Healthcare Provider

This patient has received ABECMA CAR T cell therapy, a BCMA-directed genetically modified autologous T cell immunotherapy.



Following treatment with ABECMA, cytokine release syndrome (CRS) or neurologic toxicities may occur, which may be fatal or life-threatening. CRS may involve any organ system.

Contact Patient's Oncologist Immediately for Further Information and in the Following Situations:

- The administration of steroids or cytotoxic medications.
- If the patient has a serious infection.
- Any planned invasive procedure(s) for the patient.